Recombinant monoclonal antibody to CLDN3. Chimeric CDN28 is a chimeric anitbody (mouse/human) that can be potentially used in the treatment of ovarian cancer, prostate cancer and breast cancer.
Figure 1 shows the anti-Claudin 3 antibody-mediated induction of complement-dependent cytotoxic activity against MCF7 cells. The vertical axis indicates the specific chromium release rate (%).
Figure 2 shows, by flow cytometry, the specific binding of recombinant chimeric antibodies to cells forced to express Claudin 3. The vertical axis indicates cell count (fluorescence coefficient), and the horizontal axis indicates fluorescence intensity.
Figure 3 is a graph showing suppression of the proliferation of MCF7 cells by anti-Claudin 3 antibodies in a soft agar colony formation/MTT hybrid assay.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-610-VHH | Recombinant Anti-Human CLDN3 VHH Single Domain Antibody | ELISA, Neut, ICC, FC | Llama VHH |
There are currently no Customer reviews or questions for TAB-498LC. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.